Hongjing Xia
Principal Scientist Novartis
Hongjing has led the CAR T therapy development spanning ex vivo autologous and allogeneic CAR T, in vivo mRNA LNP CAR T, and now focus on next generation delivery technologies targeting autoimmune and rare diseases.
Seminars
